IRVINE, Calif. — December 13, 2022 — Immunis, Inc., a private biotech company developing a novel treatment for age and disease-related immune decline, announces that its Chairman, Hans Keirstead, Ph.D., was appointed to the Board of Directors of the Human Immunome Project. The Human Immunome Project is a global initiative that combines breakthrough advances in biomedicine and artificial intelligence to provide a more sophisticated understanding of human immunity and disease. An elite team of scientists are using AI to compile and assess the largest dataset of biomedicine to create superior models of immune system function and precision drug targeting, thus facilitating diagnosis and treatment of disease.

An internationally renowned stem cell expert and drug developer, Dr. Keirstead has pioneered therapies for immune disorders, cancer, motor neuron diseases, spinal cord injury and retinal diseases. He has over three decades of experience leading investigations on regenerative medicine. As the Chairman of Immunis, which investigates an immunomodulatory secretome product for the various manifestations of age and disease-related immune decline, Dr. Keirstead is honored to lend his expertise to such a humanitarian cause.

“The complexity of the immune system puts the Human Immunome Project on par with the greatest scientific endeavors ever undertaken by the global scientific community,” said Hans S. Keirstead, Ph.D. “The implications and value to humanity cannot be overstated.”

About Human Immunome Project

The Human Immunome Project highlights humanity’s fight against devastating diseases by exploring the intricacies of human immunity. Their mission is to develop the first AI model of the human immunome to create new vaccines, diagnostics and treatments. The project has the long-term goal of enabling people to live much longer and healthier lives. For additional information about the Human Immunome Project please visit: www.humanimmunomeproject.org

About Immunis Inc.

Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The STEM product line leverages Immunis’ leading-edge capabilities in stem cell technologies to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ IMM01-STEM Phase 1/2a trial please visit: www.immunisbiomedical.com

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.